Blog

New Strategic Partnership with AstraZeneca

Today we announced a major milestone in the shape of a long-term strategic collaboration with AstraZeneca.

This partnership combines BenevolentAI’s expertise in AI and machine learning to identify novel insights from scientific data with AstraZeneca’s excellence in R&D to identify new targets in two therapeutic areas of huge unmet need: Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD).

The collaboration is important for BenevolentAI as it comes with an upfront payment, development milestone payments and tiered royalties on future revenues.  But, more importantly, the spirit of this deal is different. Rather than a standard service provision agreement, this deal represents a true partnership: combining AstraZeneca’s world-leading disease area expertise and large diverse datasets together with our machine learning discovery and AI-enabled target ID capabilities.

AstraZeneca and BenevolentAI will work side by side in joint multidisciplinary teams, integrating working practices across data science, machine learning, respiratory and cardiovascular R&D, Target ID and precision medicine to break down traditional drug discovery boundaries and enable more efficient data-driven decision making. The combined AstraZeneca/BenevolentAI teams will incorporate proprietary data, tailor approaches to using that data, jointly interpret the results and then work together to identify targets that we hope will lead to new medicines.

Partnerships aren’t forged on paper. In all our interactions to date, AstraZeneca has proven to be open, progressive and committed to working together. Both companies share a common purpose and mindset in unlocking the power of scientific data to make more effective drugs for the people that need them and I’m incredibly excited to combine forces with them on targeting two critical disease areas that affect the lives of millions of people.

Joanna Shields, CEO

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021